Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study

Jun 17 2019

• By Alex Shimmings

Human kidney on scientific background. 3d illustration — • Source: Shutterstock

Related Content

Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor

Jan 30 2017

Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

Apr 06 2018

Related Companies

Calithera Biosciences, Inc.

Pfizer Inc.

Ipsen SA

Rhizen Pharmaceuticals S.A.

Merck & Co., Inc.

Additional Topics

Clinical Trials Companies Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.